2-(4-nitrophenoxy)methylpyridine | 145654-42-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-nitrophenoxy)methylpyridine
• 英文别名: 2-(4-nitrophenoxymethyl)pyridine；2-[(4-Nitrophenoxy)methyl]pyridine
• CAS: 145654-42-8
• 化学式: C₁₂H₁₀N₂O₃
• 分子量: 230.223
• InChiKey: IZTWAVBPNFMQSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(4-nitrophenoxy)methylpyridine 在 盐酸 、 三乙胺 、 tin(ll) chloride 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 5-Methyl-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid [4-(pyridin-2-ylmethoxy)-phenyl]-amide
  参考文献：
  名称：

  1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists

  摘要：

  Bisarylmethoxyethers have been identified with nanomolar 5-HT2C affinity and selectivity over both 5-HT2A and 5-HT2B receptors. Compounds such as 1, 2, 8, 12, 14 and 18 have potent oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function and their therapeutic potential is currently under further investigation. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00365-6
• 作为产物：
  描述：

  2-吡啶甲醇 、 对氟硝基苯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 2-(4-nitrophenoxy)methylpyridine
  参考文献：
  名称：

  1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists

  摘要：

  Bisarylmethoxyethers have been identified with nanomolar 5-HT2C affinity and selectivity over both 5-HT2A and 5-HT2B receptors. Compounds such as 1, 2, 8, 12, 14 and 18 have potent oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function and their therapeutic potential is currently under further investigation. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00365-6

文献信息

• Studies on Antiulcer Drugs. V. Synthesis and Antiulcer Activity of Aralkylbenzazoles.
  作者：Yousuke KATSURA、Yoshikazu INOUE、Masaaki TOMOI、Hisashi TAKASUGI

  DOI：10.1248/cpb.40.2062

  日期：——

  2-alkylamino-5- or 6-aralkyl-substituted benzazoles were synthesized and tested for histamine H2-receptor antagonist and anti-stress ulcer activities. These new compounds showed little or no histamine H2-receptor antagonist activity in contrast to imidazo[1,2-a]pyridine analogues (I). On antiulcer assay, however, some pyridine derivatives (II) exerted higher activity than the reference compounds, sofalcone

  合成了一系列的2-烷基氨基-5-或6-芳烷基取代的苯并测试组胺H 2受体拮抗剂和抗应激溃疡活性。与咪唑并[1,2-a]吡啶类似物（I）相反，这些新化合物几乎没有或没有组胺H2-受体拮抗剂活性。然而，在抗溃疡试验中，一些吡啶衍生物（Ⅱ）的活性比参比化合物索法酮，硫糖铝酸盐和西咪替丁高。讨论了这些化合物的构效关系。
• Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: Design, synthesis, molecular modeling, and preliminary biological evaluation
  作者：Shirshendu DasGupta、Prashant R. Murumkar、Rajani Giridhar、Mange Ram Yadav

  DOI：10.1016/j.bmc.2009.04.003

  日期：2009.5

  tetrahydropyrimidin-2(1H)-ones were synthesized and evaluated for their TACE inhibitory activity. Most of the compounds showed very good TACE inhibitory activity. Docking study clearly indicates importance of the P1′ group of the inhibitor for the TACE inhibitory activity. This work proves that these two classes of molecules could be used as potential leads for the development of TACE inhibitors.

  合成属于2-咪唑啉酮和四氢嘧啶-2（1 H）-一类的化合物，并评价其TACE抑制活性。大多数化合物显示出非常好的TACE抑制活性。对接研究清楚地表明了抑制剂的P1'基团对TACE抑制活性的重要性。这项工作证明这两类分子可用作开发TACE抑制剂的潜在先导。
• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。
• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20090041786A1

  公开（公告）日：2009-02-12

  The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

  这项发明涵盖了具有I-V公式的化合物以及使用这些化合物在治疗需要调节JAK通路或抑制JAK激酶，特别是JAK3的情况下可能具有治疗作用的组合物和方法。
• Compositions and methods for inhibition of the jak pathway
  申请人：Li Hui

  公开号：US20060293311A1

  公开（公告）日：2006-12-28

  The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

  本发明涵盖具有I-V式的化合物，以及使用这些化合物在调节JAK通路或抑制JAK激酶，特别是JAK3，在治疗可能有治疗用途的疾病中的组合物和方法。